AstraZeneca's Lynparza Looks To Hang On To Lead, With Tesaro's Niraparib On The Way

14 Mar 2017

• By Emily Hayes

Tesaro's niraparib has an advantage over other PARP inhibitors in that it has been tested successfully in ovarian cancer patients with and without BRCA mutations, but AstraZeneca thinks it may have a case for broad labeling in this population.

AstraZeneca PLC's strong results for Lynparza in maintenance treatment of ovarian cancer could help the PARP inhibitor retain its leadership position in the class, particularly if the company persuades the US FDA to approve the drug in this indication for all comers, regardless of mutation status.

Lynparza (olaparib) was the first poly ADP-ribose polymerase (PARP) inhibitor to reach the market, in 2014, but Clovis Oncology...